We will be comparing the differences between Neurocrine Biosciences Inc. (NASDAQ:NBIX) and Aimmune Therapeutics Inc. (NASDAQ:AIMT) as far as analyst recommendations, profitability, institutional ownership, risk, dividends, earnings and valuation are concerned. The two businesses are rivals in the Biotechnology industry.

Earnings & Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neurocrine Biosciences Inc.	451.24M	17.36	21.11M	0.18	435.91
Aimmune Therapeutics Inc.	N/A	0.00	210.75M	-3.00	0.00

In table 1 we can see Neurocrine Biosciences Inc. and Aimmune Therapeutics Inc.’s gross revenue, earnings per share and valuation.

Profitability

Table 2 hightlights the return on equity, net margins and return on assets of the two companies.

	Net Margins	Return on Equity	Return on Assets
Neurocrine Biosciences Inc.	4.68%	5.1%	2.4%
Aimmune Therapeutics Inc.	0.00%	-67.2%	-59.2%

Risk & Volatility

Neurocrine Biosciences Inc. is 86.00% more volatile than Standard and Poor’s 500 because the company has a beta of 1.86. Aimmune Therapeutics Inc. on the other hand, has -0.13 beta which makes it 113.00% less volatile compared to Standard and Poor’s 500.

Liquidity

The Current Ratio and a Quick Ratio of Neurocrine Biosciences Inc. are 8.4 and 8.2. Competitively, Aimmune Therapeutics Inc. has 7 and 7 for Current and Quick Ratio. Neurocrine Biosciences Inc.’s better ability to pay short and long-term obligations than Aimmune Therapeutics Inc.

Analyst Recommendations

The Recommendations and Ratings for Neurocrine Biosciences Inc. and Aimmune Therapeutics Inc. are featured in the next table.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Neurocrine Biosciences Inc.	0	3	6	2.67
Aimmune Therapeutics Inc.	0	0	0	0.00

Neurocrine Biosciences Inc.’s upside potential is 26.10% at a $108.75 consensus target price.

Insider & Institutional Ownership

Institutional investors held 0% of Neurocrine Biosciences Inc. shares and 83.3% of Aimmune Therapeutics Inc. shares. Neurocrine Biosciences Inc.’s share held by insiders are 1.2%. Comparatively, 0.1% are Aimmune Therapeutics Inc.’s share held by insiders.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Neurocrine Biosciences Inc.	-2.53%	-10.56%	-11.62%	-35.15%	-6.23%	10.49%
Aimmune Therapeutics Inc.	2.14%	5.36%	0.16%	-11.91%	-24.45%	3.6%

For the past year Neurocrine Biosciences Inc.’s stock price has bigger growth than Aimmune Therapeutics Inc.

Summary

Neurocrine Biosciences Inc. beats Aimmune Therapeutics Inc. on 11 of the 11 factors.

Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States and internationally. The company’s lead products include INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2) used for the treatment of movement disorders; elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that is in Phase III clinical trials used for women’s health; and opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trials used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson’s disease. It is also developing NBI-640756 that is in Phase I clinical trials used for the treatment of essential tremor; and NBI-74788, which is in Phase I clinical trials used for the treatment of classic congenital adrenal hyperplasia. In addition, the company’s research programs comprise VMAT2 Inhibitors for movement disorders, bipolar disorders, and schizophrenia; and G Protein-Coupled Receptors and Ion Channels for epilepsy, essential tremor, pain, and other Indications. It has collaborations with AbbVie Inc. to develop and commercialize elagolix and GnRH antagonists for women’s and men’s health; Mitsubishi Tanabe Pharma Corporation to develop and commercialize INGREZZA for movement disorders; and BIAL – Portela & Ca, S.A. to develop and commercialize opicapone for the treatment of human diseases and conditions, including Parkinson’s disease. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.

Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies in the United States and Europe. Its lead Characterized Oral Desensitization ImmunoTherapy product candidate is AR101, an investigational biologic for the treatment of patients with peanut allergy. Aimmune Therapeutics, Inc. has strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015. The company was founded in 2011 and is headquartered in Brisbane, California.